- call +1-201-465-4211
- email sales@mrinsights.biz
According to this study, over the next five years the Amyotrophic Lateral Sclerosis (ALS) Treatment market will register a 7.2% CAGR in terms of revenue, the global market size will reach $ 353.8 million by 2025, from $ 268.3 million in 2019. In particular, this report presents the global revenue market share of key companies in Amyotrophic Lateral Sclerosis (ALS) Treatment business, shared in Chapter 3.
This report presents a comprehensive overview, market shares and growth opportunities of Amyotrophic Lateral Sclerosis (ALS) Treatment market by type, application, key companies and key regions.
This study considers the Amyotrophic Lateral Sclerosis (ALS) Treatment value generated from the sales of the following segments:
Segmentation by type: breakdown data from 2015 to 2020 in Section 2.3; and forecast to 2025 in section 10.7.
Riluzole
Edaravone (Radicava)
Other
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2025 in section 10.8.
Hospital
Drugs Store
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Mitsubishi Tanabe Pharma
Sanofi
Apotex
Glemark Generics
Mylan Pharma
Lunan Pharma
Covis Pharma
Sun Pharma
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Amyotrophic Lateral Sclerosis (ALS) Treatment market size by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Amyotrophic Lateral Sclerosis (ALS) Treatment market by identifying its various subsegments.
Focuses on the key global Amyotrophic Lateral Sclerosis (ALS) Treatment players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Amyotrophic Lateral Sclerosis (ALS) Treatment with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Amyotrophic Lateral Sclerosis (ALS) Treatment submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size 2015-2025
2.1.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size CAGR by Region
2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Type
2.2.1 Riluzole
2.2.2 Riluzole
2.2.3 Other
2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
2.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Market Share by Type (2015-2020)
2.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type (2015-2020)
2.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Application
2.4.1 Hospital
2.4.2 Drugs Store
2.4.3 Other
2.5 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
2.5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Market Share by Application (2015-2020)
2.5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Application (2015-2020)
3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment by Players
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Market Share by Players
3.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Players (2018-2020)
3.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Market Share by Players (2018-2020)
3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Amyotrophic Lateral Sclerosis (ALS) Treatment by Regions
4.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Regions
4.2 Americas Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth
4.3 APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth
4.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth
4.5 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth
5 Americas
5.1 Americas Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Countries
5.2 Americas Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
5.3 Americas Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Regions
6.2 APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
6.3 APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment by Countries
7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment by Countries
8.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
8.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast
10.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecast (2021-2025)
10.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Regions
10.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Regions (2021-2025)
10.2.2 Americas Market Forecast
10.2.3 APAC Market Forecast
10.2.4 Europe Market Forecast
10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
10.3.1 United States Market Forecast
10.3.2 Canada Market Forecast
10.3.3 Mexico Market Forecast
10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
10.4.1 China Market Forecast
10.4.2 Japan Market Forecast
10.4.3 Korea Market Forecast
10.4.4 Southeast Asia Market Forecast
10.4.5 India Market Forecast
10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
10.5.1 Germany Market Forecast
10.5.2 France Market Forecast
10.5.3 UK Market Forecast
10.5.4 Italy Market Forecast
10.5.5 Russia Market Forecast
10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
10.6.1 Egypt Market Forecast
10.6.2 South Africa Market Forecast
10.6.3 Israel Market Forecast
10.6.4 Turkey Market Forecast
10.6.5 GCC Countries Market Forecast
10.7 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Type
10.8 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Application
11 Key Players Analysis
11.1 Mitsubishi Tanabe Pharma
11.1.1 Company Details
11.1.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
11.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2018-2020)
11.1.4 Main Business Overview
11.1.5 Mitsubishi Tanabe Pharma News
11.2 Sanofi
11.2.1 Company Details
11.2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
11.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2018-2020)
11.2.4 Main Business Overview
11.2.5 Sanofi News
11.3 Apotex
11.3.1 Company Details
11.3.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
11.3.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2018-2020)
11.3.4 Main Business Overview
11.3.5 Apotex News
11.4 Glemark Generics
11.4.1 Company Details
11.4.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
11.4.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2018-2020)
11.4.4 Main Business Overview
11.4.5 Glemark Generics News
11.5 Mylan Pharma
11.5.1 Company Details
11.5.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
11.5.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2018-2020)
11.5.4 Main Business Overview
11.5.5 Mylan Pharma News
11.6 Lunan Pharma
11.6.1 Company Details
11.6.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
11.6.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2018-2020)
11.6.4 Main Business Overview
11.6.5 Lunan Pharma News
11.7 Covis Pharma
11.7.1 Company Details
11.7.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
11.7.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2018-2020)
11.7.4 Main Business Overview
11.7.5 Covis Pharma News
11.8 Sun Pharma
11.8.1 Company Details
11.8.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
11.8.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2018-2020)
11.8.4 Main Business Overview
11.8.5 Sun Pharma News
12 Research Findings and Conclusion
List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size CAGR by Region 2015-2025 ($ Millions)
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
